Metraipolis › archive › dc_7eedcce5e225

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial — Europe PMC PMID:41888141

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41888141
DOI: 10.1038/s41467-[numero omesso]-x
License (as archived): solo-consultazione
Archived: 2026-11-03T21:29:48.910Z
SHA-256 of the archived text: 22d90da82861d674f87455a0c1bda6390069551ddc5ee9a3394893135ee59351
Stable URL of this page: https://metraipolis.com/documento/dc_7eedcce5e225

How to cite

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial — Europe PMC PMID:41888141 — Europe PMC (en), https://europepmc.org/article/MED/41888141 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7eedcce5e225 (Metraipolis archive dc_7eedcce5e225, sha256 22d90da82861d674f87455a0c1bda6390069551ddc5ee9a3394893135ee59351)

BibTeX

@misc{dc7eedcce5e225,
  title = {Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial — Europe PMC PMID:41888141},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41888141},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7eedcce5e225; sha256 22d90da82861d674f87455a0c1bda6390069551ddc5ee9a3394893135ee59351},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41888141. Agents can read the archived copy with the MCP tool read_document.